NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions

Carcinoma, Non-Small-Cell LungCutaneous MelanomaCarcinoma, Renal CellCarcinoma, Ovarian EpithelialNasopharyngeal CarcinomaCarcinoma, ThymicAnal CancerMesotheliomaEsophagogastric CancerHigh Microsatellite Instability Colorectal CarcinomaSquamous Cell Carcinoma of Head and NeckTriple Negative Breast Neoplasms

Interventions

DRUG

KFA115

Immunomodulatory agent

DRUG

pembrolizumab

Anti-PD-1 antibody

Trial Locations (19)

10002

RECRUITING

Novartis Investigative Site, Taipei

10015

RECRUITING

NYU School of Medicine, New York

15232

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

20133

RECRUITING

Novartis Investigative Site, Milan

37203

RECRUITING

SCRI Oncology Partners, Nashville

41124

RECRUITING

Novartis Investigative Site, Modena

45147

RECRUITING

Novartis Investigative Site, Essen

69373

RECRUITING

Novartis Investigative Site, Lyon

100036

RECRUITING

Novartis Investigative Site, Beijing

119074

RECRUITING

Novartis Investigative Site, Singapore

510080

RECRUITING

Novartis Investigative Site, Guangzhou

999077

RECRUITING

Novartis Investigative Site, Hong Kong

02114

RECRUITING

Massachusetts General Hospital ., Boston

RECRUITING

Massachusetts General Hospital, Boston

M5G 2M9

RECRUITING

Novartis Investigative Site, Toronto

01307

RECRUITING

Novartis Investigative Site, Dresden

104 0045

RECRUITING

Novartis Investigative Site, Chuo Ku

03080

RECRUITING

Novartis Investigative Site, Seoul

08035

RECRUITING

Novartis Investigative Site, Barcelona